(Q42279944)

English

Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.

scientific article published on 31 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 October 2017

Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. (English)

1 reference

Europe PubMed Central

19 October 2017

1 reference

based on heuristic

inferred from title

José María Bayas

2

object named as

José M Bayas

1 reference

Europe PubMed Central

19 October 2017

author name string

Roman Chlibek

1

1 reference

Europe PubMed Central

19 October 2017

Harry Collins

3

1 reference

Europe PubMed Central

19 October 2017

Maria Luisa Rodriguez de la Pinta

4

1 reference

Europe PubMed Central

19 October 2017

Edouard Ledent

5

1 reference

Europe PubMed Central

19 October 2017

Johann F Mols

6

1 reference

Europe PubMed Central

19 October 2017

Thomas C Heineman

7

1 reference

Europe PubMed Central

19 October 2017

language of work or name

0 references

publication date

31 July 2013

1 reference

Europe PubMed Central

19 October 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Journal of Infectious Diseases

1 reference

Europe PubMed Central

19 October 2017

208

1 reference

Europe PubMed Central

19 October 2017

12

1 reference

Europe PubMed Central

19 October 2017

1953-1961

1 reference

Europe PubMed Central

19 October 2017

Advances in the understanding of the pathogenesis and epidemiology of herpes zoster

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Vaccine adjuvants: putting innate immunity to work

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT365

21 January 2018

Identifiers

10.1093/INFDIS/JIT365

1 reference

Europe PubMed Central

19 October 2017

1 reference

Europe PubMed Central

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42279944&oldid=2093746349"